Takeda Pharmaceutical TAK
NYSE TAK
$18.13 -0.22 (-1.17%)
As of: Aug 20, 2026 · 3:59 PM EDT

Takeda Pharmaceutical (TAK) Cash from Investing Activities (2018 - 2026)

Takeda Pharmaceutical (TAK) posted quarterly Cash from Investing Activities of -$550.2 million for Q2 2026, down 139.86% year-over-year from $1.4 billion in Q2 2025, and down 48.73% quarter-over-quarter from -$369.9 million in Q1 2026.

Takeda Pharmaceutical (TAK) Cash from Investing Activities (2018 - 2026) Analysis & Trends

Takeda Pharmaceutical's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$550.2 million for Q2 2026.

  • In Q2 2026, Cash from Investing Activities fell 139.86% year-over-year to -$550.2 million; the TTM figure through Jun 2026 stood at -$2.7 billion (down 68.91% YoY), while the FY2026 annual figure was -$2.5 billion, down 1.77% from the prior year.
  • Cash from Investing Activities for Q2 2026 stood at -$550.2 million, down from -$369.9 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was -$129.0 million in Q1 2025, with the low at -$3.3 billion in Q1 2023.
  • The 5-year median for Cash from Investing Activities is -$461.6 million (2024), against an average of -$747.4 million.
  • The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities slumped 1402.64% in 2023, then surged 87.48% in 2024.
  • Takeda Pharmaceutical's Cash from Investing Activities stood at -$330.5 million in 2022, then plunged by 54.08% to -$509.2 million in 2023, then slumped by 49.27% to -$760.1 million in 2024, then plunged by 96.45% to -$1.5 billion in 2025, then soared by 63.15% to -$550.2 million in 2026.
  • Business Quant data shows TAK's Cash from Investing Activities at -$550.2 million in Q2 2026, -$369.9 million in Q1 2026, and -$1.5 billion in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 43.83 Bn 42.86 Bn - -
2 Teva Pharmaceutical Industries 42.87 Bn 39.22 Bn 2.15 Bn -491.00 Mn
3 Zoetis 31.41 Bn 29.73 Bn 1.05 Bn -300.00 Mn
4 Takeda Pharmaceutical 28.55 Bn 22.75 Bn 5.10 Bn -550.24 Mn
5 United Therapeutics 22.08 Bn 19.42 Bn 683.80 Mn 87.50 Mn
6 Viatris 18.73 Bn 17.84 Bn 1.46 Bn -51.60 Mn
7 Neurocrine Biosciences 15.44 Bn 15.05 Bn 935.80 Mn -135.40 Mn
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn -110.00 Mn
9 Dr Reddys Laboratories 10.11 Bn 9.94 Bn - -
10 Alkermes 8.02 Bn 7.37 Bn 397.90 Mn -2.41 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -550.24 Mn
Jun 30, 2026 -550.24 Mn
Mar 31, 2026 -369.95 Mn
Mar 31, 2026 -369.95 Mn
Dec 31, 2025 -1.49 Bn
Dec 31, 2025 -1.49 Bn
Sep 30, 2025 -326.67 Mn
Sep 30, 2025 -326.67 Mn
Jun 30, 2025 -229.40 Mn
Jun 30, 2025 -229.40 Mn
Mar 31, 2025 -129.00 Mn
Mar 31, 2025 -129.00 Mn
Dec 31, 2024 -760.09 Mn
Dec 31, 2024 -760.09 Mn
Sep 30, 2024 -503.69 Mn
Sep 30, 2024 -503.69 Mn
Jun 30, 2024 -1.01 Bn
Jun 30, 2024 -1.01 Bn
Mar 31, 2024 -414.88 Mn
Mar 31, 2024 -414.88 Mn